A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer (J2258)
An Evolutionary Double Bind Phase II Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer Eligible for Prostatectomy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Dr. Ken Pienta, M.D.
- Phone Number: 410-502-3137
- Email: kpienta1@jhmi.edu
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willing and able to provide written informed consent.
- Age ≥ 18 years
- Eastern cooperative group (ECOG) performance status ≤2
- Documented histologically confirmed adenocarcinoma of the prostate
- Willing to undergo prostatectomy as primary treatment for localized prostate cancer
- Regional prostate cancer (per National Comprehensive Cancer Network criteria): T1-4, N1, M0. Patients with negative conventional imaging may have regional prostate cancer defined by PSMA PET imaging.
- Serum testosterone ≥150 ng/dL
- Able to swallow the study drugs whole as tablets
- Willing to take abiraterone acetate on an empty stomach (no food should be consumed at least two hours before and for one hour after dosing).
- Willing to use a condom if having sex with a pregnant woman, or use a condom and another effective method of birth control if having sex with a woman of childbearing potential. These measures are required during and for one week after treatment with abiraterone acetate.
Exclusion Criteria:
- Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation therapy, brachytherapy)
- Prior use of enzalutamide, apalutamide, darolutamide or abiraterone acetate
Prior or ongoing systemic therapy for prostate cancer including, but not limited to:
- androgen deprivation therapy (e.g. leuprolide, goserelin, triptorelin, degarelix)
- Cytochrome CYP-17 inhibitors (e.g. ketoconazole)
- Treatment with 1st generation antiandrogen (e.g. bicalutamide) allowed if less than one month of therapy
- Immunotherapy (e.g. sipuleucel-T, ipilimumab)
- Chemotherapy (e.g. docetaxel, cabazitaxel)
- Evidence of serious and/or unstable pre-existing medical, psychiatric, or other conditions (including laboratory abnormalities) that could interfere with patient safety or the provision of informed consent to participate in this study.
- Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule.
- Abnormal bone marrow function [absolute neutrophil count (ANC)<1500/mm3, platelet count <100,000/mm3, hemoglobin <9 g/dL]
- Abnormal liver function (bilirubin, Aspartate transaminase (AST), Alanine Transaminase (ALT) ≥ 3 x upper limit of normal)
- Abnormal kidney function (serum creatinine ≥ 2 x upper limit of normal)
- Abnormal cardiac function as manifested by the New York Heart Association (NYHA) class III or IV heart failure or history of a prior myocardial infarction (MI) within the last five years before enrollment in the study.
- History of prior cardiac arrhythmia
- Baseline pulse oximetry of <90%
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Open-Label Treatment Group
Participants will be treated with neoadjuvant therapy for a total of 3 months (12 weeks) prior to prostatectomy.
Therapy will consist of leuprolide acetate, abiraterone acetate, and belzutifan.
|
Each drug will be dosed at its respective FDA-approved dose.
These dosages are as follows: leuprolide acetate 22.5 mg depot injection x one dose, abiraterone acetate 1000 mg by mouth daily, and belzutifan120 mg administered by mouth once daily.
All men will also be treated with prednisone 5 mg by mouth twice daily while on abiraterone acetate in order to blunt its associated mineralocorticoid side effects
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of near pathological complete response (pCR)
Time Frame: 12 weeks
|
The rate of near pathological complete response (i.e.
≤5 mm of residual tumor) as assessed on prostatectomy specimens following 3-months (12 weeks) of neoadjuvant leuprolide acetate, abiraterone acetate, and belzutifan.
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Negative Margin Rate
Time Frame: 12 weeks
|
The negative margin rate as assessed on prostatectomy specimens following 3-months (12 weeks) of neoadjuvant treatment
|
12 weeks
|
|
Rate of Pathologic T3 disease
Time Frame: 12 weeks
|
The rate of pathologic T3 disease as assessed on prostatectomy specimens following 3-months (12 weeks) of neoadjuvant treatment.
|
12 weeks
|
|
Rate of radiographic disappearance of prostate nodules
Time Frame: 12 weeks
|
Rate of radiographic disappearance of MRI detectable significant prostate nodules (i.e.
≥0.5 cm in size) following 3-months (12 weeks) of neoadjuvant treatment.
|
12 weeks
|
|
Proportion of participants receiving adjuvant radiation therapy
Time Frame: Up to 1 year after prostatectomy
|
The proportion of men who receive adjuvant radiation therapy within 1-year of prostatectomy.
|
Up to 1 year after prostatectomy
|
|
Biochemical progression measured by Prostate Specific Antigen (PSA)
Time Frame: 2 years
|
The biochemical (i.e.
PSA) progression free survival estimate two years after the last patient has accrued (i.e.
confirmed PSA post-radical prostatectomy ≥0.2 ng/mL).
|
2 years
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival Estimate of Participants
Time Frame: 2 years
|
The overall survival estimate two years after the last patient has accrued.
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ken Pienta, M.D, Johns Hopkins University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Leuprolide
- Abiraterone Acetate
- Belzutifan
Other Study ID Numbers
Other Study ID Numbers
- J2258
- IRB00338335 (Other Identifier: JHM IRB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.